dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Perez-Fidalgo, J. A. |
dc.contributor.author | Cortés, A. |
dc.contributor.author | Guerra, Eva |
dc.contributor.author | García, Y. |
dc.contributor.author | Iglesias, M. |
dc.contributor.author | Bohn Sarmiento, U. |
dc.contributor.author | Oaknin Benzaquen, Ana Mazaltob |
dc.date.accessioned | 2022-03-23T12:18:26Z |
dc.date.available | 2022-03-23T12:18:26Z |
dc.date.issued | 2021-08 |
dc.identifier.citation | Perez-Fidalgo JA, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, et al. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO open. 2021 Aug;6(4):100212. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/7255 |
dc.description | Inhibidor de PARP; Olaparib; Càncer d'ovari recurrent resistent al platí |
dc.description.sponsorship | This work was supported by Grupo Español de Investigación en Cáncer de Ovario (GEICO) (no grant number). AstraZeneca provided olaparib and awarded a grant to GEICO (no grant number) to pay the costs of the study but did not take part in the conduct of the current clinical trial or in the analysis and interpretation of the results. Pegylated ribosomal doxorubicin was provided by the sites according to local standard procedures. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;6(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Quimioteràpia combinada |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Ovaris - Càncer - Tractament |
dc.subject.mesh | Ovarian Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /therapeutic use |
dc.title | Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2021.100212 |
dc.subject.decs | neoplasias ováricas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2021.100212 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Perez-Fidalgo JA] Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain. [Cortés A, Guerra E] Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. [García Y] Department of Medical Oncology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain. [Iglesias M] Department of Medical Oncology, Hospital Son Llatzer, Palma De Mallorca, Spain. [Bohn Sarmiento U] Department of Medical Oncology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas De Gran Canaria, Spain. [Oaknin A] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34329939 |
dc.identifier.wos | 000703610200048 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |